Skip to content
Evigrade
ModerateDirect oral anticoagulants (factor Xa inhibitors)×Reversible P2Y12 receptor inhibitor

Updated · Methodology

Mechanism

Edoxaban directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Ticagrelor reversibly blocks the platelet P2Y12 receptor and so prevents platelet activation and aggregation (ticagrelor SmPC, EMA). The edoxaban SmPC lists P2Y12 inhibitors among drugs that affect haemostasis and may increase the risk of bleeding (EMA). Ticagrelor weakly inhibits P-glycoprotein (P-gp) and may increase exposure to P-gp substrates. Edoxaban is a P-gp substrate. The effect of ticagrelor on edoxaban levels has not been studied (ticagrelor and edoxaban SmPCs, EMA).

Symptoms

The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, bleeding into the skin and soft tissues, and vaginal bleeding (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA).

Management

There is no contraindication for this pair. If the combination is clinically indicated, use ticagrelor with caution. This applies to patients who, within 24 hours of a ticagrelor dose, take drugs that may increase the risk of bleeding, oral anticoagulants included. In patients at known high risk of bleeding, weigh the benefit of ticagrelor against that risk (ticagrelor summary of product characteristics, SmPC, European Medicines Agency, EMA). Ticagrelor is taken with a low maintenance dose of acetylsalicylic acid, 75–150 mg a day, unless acetylsalicylic acid is contraindicated (EMA). Experience with edoxaban and dual antiplatelet therapy is very limited (edoxaban SmPC, EMA). Ticagrelor is not among the P-glycoprotein (P-gp) inhibitors that call for reducing the edoxaban dose to 30 mg once daily (ciclosporin, dronedarone, erythromycin, ketoconazole). Edoxaban has not been studied with other P-gp inhibitors (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA). Before elective surgery, if an antiplatelet effect is not needed, stop ticagrelor 5 days in advance (ticagrelor SmPC, EMA). If anticoagulation has to be interrupted, stop edoxaban as early as possible, preferably at least 24 hours before the procedure (edoxaban SmPC, EMA). According to the US edoxaban label, promptly evaluate any sign or symptom of blood loss in patients who also take other platelet aggregation inhibitors (edoxaban prescribing information, US Food and Drug Administration, FDA).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Edoxaban

Other interactions with Ticagrelor